Bridge to Life Ltd
$5.6K 9 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Rare Disease Therapeutics, Inc.
Rare Disease Therapeutics, Inc. reported $5,611.75 across General Payments, Research, and Ownership to 104 physicians and teaching hospitals across 104 transactions.
- $5.6K Below-median payer
- All-tracks total
- 104 Below-median volume
- Transactions
- 104 Below-median reach
- Recipients
- +$3.4K
- General Payments vs PY2023
Rare Disease Therapeutics, Inc. reported $5,611.75 across all CMS Open Payments tracks (General + Research + Ownership) to 104 physicians and teaching hospitals in Program Year 2024 - ranking #1701 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $5,611.75, averaging $53.96 per recipient.
Rare Disease Therapeutics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
10/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer rare-disease-therapeutics-inc Rare Disease Therapeutics, Inc.
$5.6K · #1701/1,925 · 0.0% industry · PY2024
- TOT $5.6K
- RANK #1701
- SHARE 0.0%
- TXN 104
- RCP 104
- CAT 2
- GEN $5.6K
- ΔGEN +$3.4K
- TOP1 62.4%
- PY 2024
Volume peers
Nearest volume peer: Bridge to Life Ltd ($5.6K)
Rare Disease Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Rare Disease Therapeutics, Inc.'s CMS-reported General Payments increased by $3.4K (+158.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: RARE DISEASE THERAPEUTICS, INC.PY2023: RARE DISEASE THERAPEUTICS, INC.PY2024: RARE DISEASE THERAPEUTICS, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,170.93
- PY2024
- $5,611.75
What the Data Shows for Rare Disease Therapeutics, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Rare Disease Therapeutics, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $3.5K, accounting for 62.4% of this company's General Payments and 1 transactions.
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Rare Disease Therapeutics, Inc.'s 2-category general-payment breakdown at $3.5K, 62.4% of the reported total.
How Rare Disease Therapeutics, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $3.5K | 1 | 62.4% |
| Food and Beverage | $2.1K | 103 | 37.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $3,690.64 (65.8%) of $5,611.75 in this company's General Payments records across 100 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Rare Disease Therapeutics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Alan Anderson
$3,500.00 across 1 reported transactions
- 2
Jonathan Meadows
$47.66 across 1 reported transactions
- 3
Alexandra Barbosa
$47.66 across 1 reported transactions
- 4
Tyler Hoelscher
$47.66 across 1 reported transactions
- 5
Adiel Aizenberg
$47.66 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Rare Disease Therapeutics, Inc. ranks #1701 of 1,925 by total payments (bottom 12% by spend) but is notably more concentrated than that alone would suggest -- #455 of 1,838 by HHI (top 25% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Prytime Medical Devices, Inc. : $265.7K total payments, HHI 3997
- Contego Medical, Inc : $340.5K total payments, HHI 3992
- Microgenics Corporation : $106.3K total payments, HHI 3980
- B. Braun Melsungen AG : $165.4K total payments, HHI 3974
- Dynavax Technologies Corporation : $446.2K total payments, HHI 3923
- Materialise USA LLC : $273.65 total payments, HHI 3922
- Rare Disease Therapeutics, Inc. (this company) : $5.6K total payments, HHI 3906
- OraSure Technologies Inc. : $211.4K total payments, HHI 3885
- Gotham Surgical Solutions & Devices, Inc. : $164.9K total payments, HHI 3883
- Surgical Theater. Inc. : $199.9K total payments, HHI 3868
- Helsinn Healthcare SA : $296.6K total payments, HHI 3863
- 4DMedical USA Inc : $233.5K total payments, HHI 3861
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Rare Disease Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Rare Disease Therapeutics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Rare Disease Therapeutics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Karl Storz Endovision, Inc.
$5.5K 3 recipients
Compare payment profiles
Granata Bio Corporation
$5.5K 22 recipients
Compare payment profiles
Aquestive Therapeutics, Inc.
$5.5K 214 recipients
Compare payment profiles
Perfuze Inc
$5.8K 5 recipients
Compare payment profiles
ReShape Lifesciences Inc.
$5.8K 15 recipients
Compare payment profiles
Put this to use
Rare Disease Therapeutics, Inc. ranks #1701 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Rare Disease Therapeutics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.